Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Care Facilities

DaVita Inc. provides a variety of health care services. The Company provides kidney dialysis services for patients suffering from chronic kidney failure. DaVita serves patients worldwide.
Website: davita.com



Growth: Pretty weak revenue growth rate 9.9%, there is acceleration compared to average historical growth rates 5.5%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of -11.9%

Profitability: LTM EBITDA margin is positive, +21.2%. On average the margin is decreasing unsteadily. Gross margin is normal, +27.0%. In the last quarter the company beat the estimated EPS, +9.6%. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.15 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -3.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 228.0% higher than minimum and 0.4% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.9x by EV / Sales multiple , the company can be 6.6% undervalued

Insiders: For the last 3 months insiders sold company shares on $35.0 mln (-0.184% of cap.)

Key Financials (Download financials)

Ticker: DVA
Share price, USD:  (+0.5%)240.09
year average price 139.23  


year start price 138.48 2025-08-02

min close price 103.87 2026-01-14

max close price 240.96 2026-07-29

current price 240.09 2026-08-01
Common stocks: 94 600 000

Dividend Yield:  0.0%
FCF Yield LTM: -3.5%
EV / LTM EBITDA: 12.7x
EV / EBITDA annualized: 12.3x
Last revenue growth (y/y):  +9.9%
Last growth of EBITDA (y/y):  +1.2%
Historical revenue growth:  +5.5%
Historical growth of EBITDA:  +20.1%
EV / Sales: 2.7x
Margin (EBITDA LTM / Revenue): 21.2%
Fundamental value created in LTM:
Market Cap ($m): 22 713
Net Debt ($m): 13 983
EV (Enterprise Value): 36 696
Price to Book: -39.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-08fool.com

2 Warren Buffett Stocks to Buy Hand Over Fist in 2026 and 1 to Avoid

2026-02-05zacks.com

Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term

2026-02-02seekingalpha.com

DaVita Inc. (DVA) Q4 2025 Earnings Call Transcript

2026-02-02zacks.com

DaVita HealthCare (DVA) Q4 Earnings and Revenues Surpass Estimates

2026-02-02reuters.com

DaVita forecasts 2026 profit above estimates on steady dialysis service demand; shares jump

2026-02-02businesswire.com

Elara Caring Secures New Strategic Investment from Ares and DaVita

2026-01-30zacks.com

Can Operational Execution Support DaVita's Q4 Performance?

2026-01-21zacks.com

DaVita HealthCare (DVA) Outperforms Broader Market: What You Need to Know

2025-12-22zacks.com

DaVita HealthCare (DVA) Beats Stock Market Upswing: What Investors Need to Know

2025-12-19zacks.com

4 Outpatient Home Health Stocks in Focus as Market Dynamics Change
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol DVA DVA DVA DVA DVA DVA DVA DVA DVA DVA DVA DVA DVA DVA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066
fillingDate 2025-10-29 2025-08-05 2024-10-29 2024-08-06 2024-05-02 2023-11-07 2023-08-03 2023-05-08 2022-10-31
acceptedDate 2025-10-29 17:05:01 2025-08-05 17:03:37 2025-02-13 17:25:47 2024-10-29 17:04:29 2024-08-06 17:03:37 2024-05-02 16:12:00 2024-02-14 17:01:00 2023-11-07 17:08:38 2023-08-03 17:07:32 2023-05-08 17:03:28 2023-02-22 17:19:41 2022-10-28 18:02:55 2022-02-11 16:07:49 2021-02-12 16:07:27
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 3 420M 3 380M 12 816M 3 264M 3 187M 3 071M 12 140M 3 121M 3 000M 2 873M 11 610M 2 949M 11 619M 11 551M
costOfRevenue 2 333M 2 262M 8 599M 2 152M 2 318M 2 079M 8 320M 2 067M 2 056M 2 058M 8 210M 2 086M 7 972M 7 989M
grossProfit 1 087M 1 118M 4 217M 1 112M 869M 992M 3 820M 1 054M 945M 815M 3 400M 863M 3 646M 3 562M
grossProfitRatio 0.318 0.331 0.341 0.273 0.323 0.338 0.315 0.284 0.293
researchAndDevelopmentExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
generalAndAdministrativeExpenses 414M 413M 1 538M 394M 368M 362M 1 474M 377M 364M 332M 1 355M 365M 1 195M 1 248M
sellingAndMarketingExpenses 0 0 0 0 9M 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 414M 413M 1 538M 394M 368M 362M 1 474M 377M 364M 332M 1 355M 365M 1 195M 1 248M
otherExpenses 167M 167M 588M 183M -27M -13M 744M -20M 1M 178M 706M 194M 654M 620M
operatingExpenses 582M 580M 2 127M 577M 368M 550M 2 218M 565M 548M 510M 2 061M 560M 1 849M 1 867M
costAndExpenses 2 914M 2 842M 10 725M 2 732M 2 686M 2 629M 10 537M 2 633M 2 604M 2 568M 10 271M 2 645M 9 821M 9 856M
interestIncome 0 0 0 0 0 0 0 126M 0 0 0 0 0 0
interestExpense 151M 146M 470M 135M 98M 99M 399M 98M 104M 101M 357M 100M 285M 304M
depreciationAndAmortization 177M 175M 724M 187M 176M 187M 745M 188M 184M 182M 733M 190M 681M 630M
ebitda 637M 690M 2 725M 698M 692M 623M 2 321M 665M 590M 493M 2 056M 501M 2 484M 2 253M
ebitdaratio 0.186 0.204 0.214 0.212 0.203 0.213 0.197 0.172 0.17
operatingIncome 506M 538M 2 090M 535M 501M 484M 1 603M 496M 405M 312M 1 339M 312M 1 797M 1 695M
operatingIncomeRatio 0.148 0.159 0.164 0.157 0.158 0.159 0.135 0.108 0.106
totalOtherIncomeExpensesNet -197M -169M -560M -161M -135M 29M -426M -12M 2M -97M -373M -105M -279M -376M
incomeBeforeTax 309M 369M 1 530M 373M 371M 372M 1 177M 378M 295M 215M 966M 207M 1 518M 1 318M
incomeBeforeTaxRatio 0.09 0.109 0.114 0.117 0.121 0.121 0.098 0.075 0.07
incomeTaxExpense 69M 94M 280M 78M 72M 66M 220M 69M 49M 44M 198M 43M 307M 314M
netIncome 150M 199M 936M 215M 223M 240M 692M 247M 179M 171M 560M 165M 978M 774M
netIncomeRatio 0.044 0.059 0.066 0.07 0.078 0.079 0.06 0.059 0.056
eps 2.09 2.62 11.02 2.56 2.56 2.73 7.62 2.7 1.96 1.89 5.88 1.81 9.3 6.54
epsdiluted 2.04 2.58 2.5 2.5 2.65 2.62 1.91 1.85 1.77
weightedAverageShsOut 72M 76M 85M 84M 87M 88M 91M 91M 91M 90M 93M 91M 105M 120M
weightedAverageShsOutDil 74M 77M 87M 86M 89M 91M 93M 94M 93M 92M 96M 93M 110M 123M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-14 2023-02-22 2022-02-11 2021-02-12
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -470M -399M -357M -285M -304M
ebit 2 001M 1 576M 1 323M 1 804M 1 622M
nonOperatingIncomeExcludingInterest 90M 27M 16M -6M 72M
netIncomeFromContinuingOperations 1 251M 957M 768M 1 212M 1 004M
netIncomeFromDiscontinuedOperations 0 0 13M 0 -10M
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 936M 692M 560M 978M 774M
epsDiluted 10.73 7.42 5.71 8.9 6.39

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol DVA DVA DVA DVA DVA DVA DVA DVA DVA DVA DVA DVA DVA DVA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066
fillingDate 2025-10-29 2025-08-05 2024-10-29 2024-08-06 2024-05-02 2023-11-07 2023-08-03 2023-05-08 2022-10-31
acceptedDate 2025-10-29 17:05:01 2025-08-05 17:03:37 2025-02-13 17:25:47 2024-10-29 17:04:29 2024-08-06 17:03:37 2024-05-02 16:12:00 2024-02-14 17:01:00 2023-11-07 17:08:38 2023-08-03 17:07:32 2023-05-08 17:03:28 2023-02-22 17:19:41 2022-10-28 18:02:55 2022-02-11 16:07:49 2021-02-12 16:07:27
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 706M 708M 795M 1 071M 503M 345M 380M 449M 327M 317M 244M 368M 462M 325M
shortTermInvestments 31M 31M 51M 21M 21M 11M 12M 12M 12M 50M 78M 74M 22M 20M
cashAndShortTermInvestments 736M 739M 846M 1 092M 524M 356M 392M 461M 340M 367M 322M 442M 484M 345M
netReceivables 2 855M 3 003M 2 558M 2 631M 2 733M 2 991M 2 416M 2 378M 2 367M 2 382M 2 551M 2 493M 2 411M 1 824M
inventory 139M 146M 135M 129M 127M 146M 143M 110M 110M 107M 109M 107M 107M 112M
otherCurrentAssets 381M 199M 208M 185M 170M 105M 187M 91M 90M 89M 174M 161M 93M 791M
totalCurrentAssets 4 112M 4 088M 3 746M 4 037M 3 467M 3 684M 3 138M 3 135M 3 002M 3 040M 3 155M 3 202M 3 168M 3 149M
propertyPlantEquipmentNet 5 608M 5 193M 5 334M 5 358M 5 440M 5 513M 5 575M 5 607M 5 706M 5 833M 5 923M 5 962M 6 305M 6 385M
goodwill 7 544M 7 466M 7 375M 7 228M 7 201M 7 230M 7 113M 7 088M 7 106M 7 090M 7 077M 7 023M 7 046M 6 919M
intangibleAssets 220M 212M 197M 198M 191M 201M 203M 185M 192M 187M 183M 180M 178M 167M
goodwillAndIntangibleAssets 7 764M 7 677M 7 573M 7 425M 7 393M 7 431M 7 316M 7 274M 7 298M 7 277M 7 259M 7 202M 7 224M 7 086M
longTermInvestments 259M 342M 370M 430M 537M 540M 594M 611M 639M 286M 275M 287M 288M 290M
taxAssets 0 0 0 51M 694M 720M 0 0 760M 771 087M 0 0 0 0
otherNonCurrentAssets 0 193M 262M 202M -505M -457M 271M 302M -446M -770 796M 316M 308M 137M 80M
totalNonCurrentAssets 13 631M 13 405M 13 539M 13 467M 13 559M 13 747M 13 756M 13 793M 13 957M 13 688M 13 773M 13 759M 13 954M 13 840M
otherAssets 0 0 0 0 0 0 0 0 0 0 1000 0 0 0
totalAssets 17 743M 17 493M 17 285M 17 504M 17 026M 17 431M 16 894M 16 929M 16 959M 16 728M 16 928M 16 962M 17 121M 16 989M
accountPayables 656M 594M 547M 488M 494M 490M 515M 435M 428M 448M 480M 417M 402M 434M
shortTermDebt 495M 612M 271M 701M 943M 529M 123M 502M 496M 637M 231M 611M 179M 169M
taxPayables 26M 20M 69M 21M 25M 83M 29M 22M 32M 65M 18M 10M 54M 8M
deferredRevenue 0 0 0 0 25M 705M 0 793M 662M 0 0 819 073M 0 0
otherCurrentLiabilities 1 840M 1 708M 1 532M 1 734M 1 533M 860M 1 424M 808M 818M 1 480M 1 350M -817 564M 1 239M 1 373M
totalCurrentLiabilities 3 017M 2 934M 2 973M 2 944M 2 995M 2 583M 2 642M 2 538M 2 403M 2 565M 2 620M 2 537M 2 399M 2 476M
longTermDebt 14 383M 12 204M 9 176M 11 497M 10 733M 11 312M 8 268M 10 627M 10 983M 10 873M 8 693M 11 426M 8 729M 7 917M
deferredRevenueNonCurrent 0 0 0 0 2 526M 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 742M 646M 665M 660M 694M 720M 726M 754M 760M 771M 783M 819M 831M 810M
otherNonCurrentLiabilities -1 927M 156M 170M 183M 179M 180M 183M 185M 183M 100M 105M -807 750M 119M 150M
totalNonCurrentLiabilities 13 198M 13 006M 12 221M 12 340M 11 606M 12 212M 11 508M 11 566M 11 926M 11 744M 12 084M 12 352M 12 352M 11 616M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 2 532M 2 554M 2 620M 2 642M 2 930M 2 713M 2 725M 2 736M 2 779M 2 850M 2 898M 2 955M 3 067M 3 108M
totalLiabilities 16 215M 15 940M 15 194M 15 284M 14 601M 14 795M 14 150M 14 104M 14 329M 14 309M 14 703M 14 889M 14 751M 14 092M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 91 000 91 000 90 000 90 000 90 000 90 000 89 000 91 000 91 000 91 000 90 000 98 000 97 000 110 000
retainedEarnings 2 047M 1 897M 1 535M 1 275M 1 061M 838M 598M 715M 469M 290M 174M 847M 354M 853M
accumulatedOtherComprehensiveIncomeLoss -116M -138M -311M -162M -195M -100M -52M -69M -7M -55M -69M -136M -139M -66M
othertotalStockholdersEquity -2 503M -2 129M -726M -233M 188M 553M 556M 590M -179M
totalStockholdersEquity -572M -370M 121M 387M 633M 926M 1 056M 1 199M 1 017M 825M 712M 533M 756M 1 384M
totalEquity 1 528M 1 553M 2 091M 2 220M 2 425M 2 636M 2 743M 2 825M 2 630M 2 419M 2 225M 533M 2 371M 2 897M
totalLiabilitiesAndStockholdersEquity 17 743M 17 493M 17 504M 17 026M 17 431M 16 929M 16 959M 16 728M 16 962M
minorityInterest 2 100M 1 923M 1 970M 1 833M 1 792M 1 710M 1 687M 1 625M 1 612M 1 593M 1 512M 0 1 615M 1 513M
totalLiabilitiesAndTotalEquity 17 743M 17 493M 17 285M 17 504M 17 026M 17 431M 16 894M 16 929M 16 959M 16 728M 16 928M 16 962M 17 121M 16 989M
totalInvestments 290M 373M 421M 451M 557M 551M 605M 622M 652M 291 712M 353M 361M 311M 310M
totalDebt 14 878M 12 815M 12 067M 12 198M 11 676M 11 841M 11 116M 11 129M 11 478M 11 509M 11 822M 12 037M 11 975M 11 194M
netDebt 14 172M 12 107M 11 272M 11 127M 11 172M 11 496M 10 736M 10 680M 11 151M 11 192M 11 578M 11 669M 11 513M 10 869M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-14 2023-02-22 2022-02-11 2021-02-12
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 2 147M 1 987M 2 132M 1 958M 1 824M
otherReceivables 411M 429M 419M 453M 0
prepaids 0 0 0 73M 76M
totalPayables 617M 590M 541M 498M 481M
otherPayables 69M 76M 61M 96M 47M
accruedExpenses 144M 110M 103M 88M 85M
capitalLeaseObligationsCurrent 410M 394M 395M 394M 369M
capitalLeaseObligationsNonCurrent 2 210M 2 330M 2 503M 2 673M 2 739M
treasuryStock -1 389M 0 0 0 0
additionalPaidInCapital 286M 510M 607M 540M 597M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol DVA DVA DVA DVA DVA DVA DVA DVA DVA DVA DVA DVA DVA DVA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066
fillingDate 2025-10-29 2025-08-05 2024-10-29 2024-08-06 2024-05-02 2023-11-07 2023-08-03 2023-05-08 2022-10-31
acceptedDate 2025-10-29 17:05:01 2025-08-05 17:03:37 2025-02-13 17:25:47 2024-10-29 17:04:29 2024-08-06 17:03:37 2024-05-02 16:12:00 2024-02-14 17:01:00 2023-11-07 17:08:38 2023-08-03 17:07:32 2023-05-08 17:03:28 2023-02-22 17:19:41 2022-10-28 18:02:55 2022-02-11 16:07:49 2021-02-12 16:07:27
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 310M 275M 1 251M 296M 223M 306M 692M 309M 246M 171M 782M 165M 1 212M 995M
depreciationAndAmortization 177M 175M 724M 187M 176M 187M 745M 188M 184M 178M 733M 194M 681M 630M
deferredIncomeTax 79M -14M -58M -25M -25M -3M -39M -2M -13M -4M -76M -45M 60M 241M
stockBasedCompensation 39M 33M 103M 27M 24M 25M 112M 27M 30M 25M 95M 28M 102M 91M
changeInWorkingCapital 462M -172M -30M 272M 277M -640M 195M 106M -5M 83M 101 000 320M -141M -104M
accountsReceivables 144M -133M -30M 17M 368M -561M 172M -23M 60M 82M -148M -4M -138M -21M
inventory 11M 5M 18M -2M 20M 2M -32M -5M -3M 3M -757 000 2M 6M -12M
accountsPayables 62M -11M 2M -4M -25M -14M 27M 7M -20M -21M 87M 14M -30M 37M
otherWorkingCapital 245M -33M -20M 261M -87M -74M 27M 127M -42M 19M 62M 307M 22M -108M
otherNonCashItems -225M 27M 32M 54M 140M 8M 354M 32M 8M 9M 30M 48M 16M 126M
netCashProvidedByOperatingActivities 841M 324M 2 022M 810M 803M -135M 2 059M 661M 450M 463M 1 565M 711M 1 931M 1 979M
investmentsInPropertyPlantAndEquipment -166M -121M -555M -139M -125M -121M -568M -137M -124M -148M -603M -144M -641M -675M
acquisitionsNet -12M 12M -251M 5M -78M -106M -26M -8M -268M -8M -89M -39M -201M -204M
purchasesOfInvestments 11M -3M -24M -24M -676 000 -3M -323M -327 000 -7M -30M -133M -5M -34M -154M
salesMaturitiesOfInvestments -45M 46M 27M 15M 7M 5M 110M 57 000 44M 54M 75M 32M 28M 155M
otherInvestingActivites -51M 0 0 6M 7M 5M 8M 15M 2M
netCashUsedForInvestingActivites -263M -67M -143M -196M -215M -140M -347M -117M -154M
debtRepayment 791M 510M 545M -141M -736M -645M -1 467M -881M -716M
commonStockIssued 18M 0 0 0 0 0 0 0 0
commonStockRepurchased -40M -452M -1 386M -434M -361M -337M -272M 2M -36M -8M -802M -179M -1 599M -1 459M
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -1 351M -54M -122M -30M -79M 248M 1 405M 613M 450M
netCashUsedProvidedByFinancingActivities -582M 4M -11M -533M 319M -395M -97M -276M -445M
effectOfForexChangesOnCash 2M 11M -18M -654 000 -1M -3M 9M -4M 5M 2M -29M -5M -10M -14M
netChangeInCash -2M 272M 415M 655M 72M -34M 126M 123M 11M 72M -216M 106M 53M -707M
cashAtEndOfPeriod 795M 797M 880M 1 159M 503M 431M 465M 545M 422M 411M 339M 462M 555M 502M
cashAtBeginningOfPeriod 797M 525M 465M 503M 431M 465M 339M 422M 411M 339M 555M 356M 502M 1 209M
operatingCashFlow 841M 324M 2 022M 810M 803M -135M 2 059M 661M 450M 463M 1 565M 711M 1 931M 1 979M
capitalExpenditure -166M -121M -555M -139M -125M -121M -568M -137M -124M -148M -603M -144M -641M -675M
freeCashFlow 675M 203M 1 467M 671M 678M -256M 1 491M 524M 326M 315M 961M 567M 1 289M 1 304M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-14 2023-02-22 2022-02-11 2021-02-12
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 33M 36M 121M 64M 53M
netCashProvidedByInvestingActivities -771M -772M -630M -785M -825M
netDebtIssuance 1 109M -553M -11M 754M -169M
longTermNetDebtIssuance 1 109M -553M -11M 754M -64M
shortTermNetDebtIssuance 0 0 0 0 -106M
netStockIssuance -1 365M -255M -784M -1 599M -1 459M
netCommonStockIssuance -1 365M -255M -784M -1 599M -1 459M
commonStockIssuance 20M 17M 19M 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -561M -363M -326M -239M -218M
netCashProvidedByFinancingActivities -817M -1 170M -1 121M -1 083M -1 847M
incomeTaxesPaid 388M 268M 344M 155M 155M
interestPaid 423M 388M 351M 279M 326M

Earning call transcript

2025 q4
2026-02-02 ET (fiscal 2025 q4)
2025 q3
2025-10-29 ET (fiscal 2025 q3)
2025 q2
2025-08-05 ET (fiscal 2025 q2)
2025 q1
2025-05-12 ET (fiscal 2025 q1)
2024 q4
2025-02-13 ET (fiscal 2024 q4)
2024 q3
2024-10-29 ET (fiscal 2024 q3)
2024 q2
2024-08-06 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-13 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-08 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-10-28 ET (fiscal 2022 q3)
2022 q2
2022-08-01 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-04-20 18:06 ET
DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call
2026-03-18 ET
DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement
2026-02-24 ET
DaVita Inc. to Participate in TD Cowen's 46th Annual Health Care Conference
2026-02-02 ET
DaVita Inc. 4th Quarter 2025 Results
2026-01-21 ET
DaVita Inc. Schedules 4th Quarter 2025 Investor Conference Call
2025-12-11 ET
DaVita Names New Leaders to Accelerate Care Transformation
2025-11-14 ET
DaVita Inc. to Participate in Fireside Chat with Wolfe Research
2025-11-04 ET
DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025
2025-10-29 ET
DaVita Inc. 3rd Quarter 2025 Results
2025-10-20 ET
DaVita Leads the Way in Evaluating Middle Molecule Clearance with Two New Initiatives
2025-10-13 ET
DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call
2025-08-27 ET
DaVita Honors 25 Years of Clinical Advancement in Chronic Disease Care
2025-08-05 ET
DaVita Inc. 2nd Quarter 2025 Results
2025-07-17 ET
DaVita Inc. Schedules 2nd Quarter 2025 Investor Conference Call
2025-05-30 ET
DaVita Statement on Government's Kidney Care Choices (KCC) Model Updates
2025-05-20 ET
DaVita Inc. Announces Upsize and Pricing of $1 Billion Senior Notes Offering
2025-05-20 ET
DaVita Releases Annual Community Care Report, Highlights Achievements in Corporate Citizenship
2025-05-20 ET
DaVita Inc. Announces Offering of $750 Million Senior Notes
2025-05-12 ET
DaVita Inc. 1st Quarter 2025 Results
2025-04-30 ET
DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call
2025-03-06 ET
DaVita Inc. to Participate in the Barclays Global Healthcare Conference 2025
2025-02-27 ET
YMCA of the USA Deepens Collaboration with DaVita to Drive Kidney Health Initiatives in Seven Communities
2025-02-13 ET
DaVita Inc. 4th Quarter 2024 Results
2025-01-30 ET
DaVita Inc. Schedules 4th Quarter 2024 Investor Conference Call
2025-01-15 ET
DaVita Celebrates 25 Years of Exceptional Patient Care, Empowering the Future of Kidney Health
2025-01-09 ET
DaVita Supports Thousands of Patients and Teammates Affected by Southern California Wildfires
2024-11-12 ET
DaVita's "Move It With Purpose" Sets Record Participation in Support of Global Health
2024-11-08 ET
DaVita Inc. to Participate in UBS Global Healthcare Conference 2024
2024-10-29 20:05 ET
DaVita Inc. 3rd Quarter 2024 Results
2024-10-28 15:05 ET
DaVita Emphasizes Commitment to Whole-Person Care with Investment in National Kidney Foundation PEERS Program
2024-10-22 12:00 ET
DaVita celebrates kidney care community achievements in year one of largest-ever value-based care program
2024-10-17 17:00 ET
DaVita Appoints Jessica Hergenreter as Chief People Officer
2024-10-11 19:58 ET
DaVita Opens its Doors to Anyone in Florida Needing Dialysis After Hurricane Milton
2024-10-09 17:47 ET
DaVita Inc. Schedules 3rd Quarter 2024 Investor Conference Call
2024-10-08 17:38 ET
DaVita Prepares Thousands of Dialysis Patients for Hurricane Milton
2024-09-17 13:00 ET
DaVita Accelerates Commitment to Community Health with Nationwide Tour
2024-09-13 12:00 ET
DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role
2024-08-08 13:16 ET
DaVita Inc. Announces Offering of $1.0 Billion Senior Notes
2024-08-06 20:05 ET
DaVita Inc. 2nd Quarter 2024 Results
2024-07-18 18:00 ET
DaVita Inc. Schedules 2nd Quarter 2024 Investor Conference Call
2024-05-14 13:00 ET
DaVita Celebrates Corporate Citizenship Achievements with Release of 2023 Community Care Report
2024-05-13 13:00 ET
DaVita Appoints New Chief Information Officer
2024-05-09 22:15 ET
DaVita Inc. to Participate in the BofA Securities 2024 Health Care Conference
2024-05-09 14:00 ET
DaVita Honors 54 Nephrology Nurses with DAISY Awards
2024-05-02 20:05 ET
DaVita Inc. 1st Quarter 2024 Results
2024-04-22 13:00 ET
DaVita's Global Operations Powered by 100% Renewable Energy
2024-04-17 23:31 ET
DaVita Inc. Schedules 1st Quarter 2024 Investor Conference Call
2024-04-10 13:00 ET
DaVita Announces Dennis Pullin to its Board of Directors
2024-03-11 20:40 ET
The American Diabetes Association and DaVita Strengthen Alliance to Tackle Chronic Disease Head-On
2024-03-08 22:20 ET
DaVita Inc. to Participate in the Barclays Global Healthcare Conference 2024
2024-03-05 14:00 ET
DaVita enters into agreement to expand operations in Brazil and Colombia, enter Chile and Ecuador
2024-03-01 00:19 ET
DaVita Inc. to Participate in the TD Cowen's Health Care Conference 2024
2024-02-13 21:08 ET
DaVita Inc. 4th Quarter 2023 Results
2024-01-23 19:00 ET
DaVita Inc. Schedules 4th Quarter 2023 Investor Conference Call
2023-12-19 15:00 ET
DaVita Giving Foundation Invests $1 Million in Western Governors University to Support Nursing Students
2023-12-19 ET
DaVita Giving Foundation Invests $1 Million in Western Governors University to Support Nursing Students
2023-11-30 15:00 ET
DaVita's 'Move It With Purpose' Event Achieves Record-Breaking Participation to Support Life-Saving Care
2023-11-07 21:05 ET
DaVita Inc. 3rd Quarter 2023 Results
2023-11-02 16:05 ET
DaVita Unveils New Research to Drive Health Equity and Improve Care Quality during Annual American Society of Nephrology Meeting
2023-10-18 16:00 ET
DaVita Collaborates with Google Cloud to Develop Customized Clinical Operating System Designed to Transform Kidney Care
2023-10-17 22:26 ET
DaVita Inc. Schedules 3rd Quarter 2023 Investor Conference Call
2023-10-12 12:30 ET
DaVita Statement on GLP-1 and Potential Implications on Chronic Kidney Disease
2023-09-13 12:15 ET
DaVita launches community health tour to provide free kidney screenings and education coast-to-coast
2023-09-11 20:54 ET
DaVita Inc. to Participate in Fireside Chat with UBS
2023-08-03 20:05 ET
DaVita Inc. 2nd Quarter 2023 Results
2023-07-13 21:05 ET
DaVita Announces Wendy Schoppert to Join its Board of Directors
2023-07-13 20:00 ET
DaVita Inc. Schedules 2nd Quarter 2023 Investor Conference Call
2023-05-10 10:02 ET
DaVita Recognizes Nephrology Nurses with DAISY Award
2023-05-08 20:05 ET
DaVita Inc. 1st Quarter 2023 Results
2023-05-04 10:02 ET
DaVita Celebrates Corporate Citizenship Achievements, Releases its 2022 Community Care Report
2023-05-02 19:51 ET
DaVita Inc. to Participate in the BofA Securities Healthcare Conference 2023
2023-04-18 17:30 ET
DaVita Inc. Schedules 1st Quarter 2023 Investor Conference Call
2023-04-04 12:04 ET
LEX FERENDA LITIGATION FUNDING EXPANDS TO DENVER; ANNOUNCES ADDITION OF PROMINENT LITIGATOR AND IN-HOUSE ATTORNEY ANDREW KELLEY
2023-03-13 19:34 ET
DaVita Inc. to Participate in the Barclays 2023 Global Healthcare Conference
2023-02-22 21:05 ET
DaVita Inc. 4th Quarter 2022 Results
2023-02-01 10:00 ET
DaVita Inc. Schedules 4th Quarter 2022 Investor Conference Call
2023-01-31 11:02 ET
DaVita Emphasized Holistic Care for Kidney Patients and Teammates in 2022
2022-12-20 11:02 ET
DaVita's Move It with Purpose Event Raises Funds for Bridge of Life
2022-11-03 10:02 ET
DaVita Clinical Research Showcases Chronic Kidney Disease and Rare Disease Network, Presents New Research Findings at Kidney Week 2022
2022-10-28 10:30 ET
DaVita Inc. 3rd Quarter 2022 Results
2022-10-14 09:00 ET
DaVita Inc. Schedules 3rd Quarter 2022 Investor Conference Call
2022-10-10 10:02 ET
The DaVita Giving Foundation Provides $1.4 Million Grant Toward Addressing Food Insecurity
2022-10-10 ET
The DaVita Giving Foundation Provides $1.4 Million Grant Toward Addressing Food Insecurity
2022-09-13 21:02 ET
DaVita Announces Adam H. Schechter to Join its Board of Directors
2022-08-01 20:05 ET
DaVita Inc. 2nd Quarter 2022 Results
2022-07-25 14:11 ET
American Diabetes Association Focuses on Prevention of Kidney Disease through Collaboration with DaVita
2022-07-18 08:05 ET
DaVita Inc. Schedules 2nd Quarter 2022 Investor Conference Call
2022-06-22 20:02 ET
Rockwell Medical Provides Corporate and Clinical Update
2022-06-22 15:06 ET
DaVita Inc. Schedules Special Investor Conference Call
2022-05-10 10:02 ET
DaVita Honors Extraordinary Nurses with DAISY Awards
2022-05-09 10:02 ET
DaVita Inc. to Participate in the Bank of America Securities 2022 Healthcare Conference
2022-05-05 20:05 ET
DaVita Inc. 1st Quarter 2022 Results
2022-05-03 10:02 ET
DaVita Celebrates 2021 ESG, Corporate Social Responsibility Achievements
2022-04-21 08:05 ET
DaVita Inc. Schedules 1st Quarter 2022 Investor Conference Call
2022-04-11 13:00 ET
Rockwell Medical Expands Partnership with DaVita
2022-04-07 22:01 ET
DaVita Announces Jason M. Hollar to Join its Board of Directors
2022-04-04 17:53 ET
New Research Affirms Increase in Access, Equity of COVID-19 Vaccines Administered in Dialysis Centers
2022-02-17 11:04 ET
DaVita Clinical Research Study Finds Efficacy of Common COVID-19 Vaccines at Parity for Kidney Patients
2022-02-16 11:02 ET
DaVita Kidney Care Appoints New Chief Medical Officer of Home Modalities
2022-02-14 11:02 ET
DaVita expands paid leave to support teammates choosing to be living organ donors
2022-02-10 21:05 ET
DaVita Inc. 4th Quarter 2021 Results
2022-01-27 21:05 ET
DaVita Inc. Schedules 4th Quarter 2021 Investor Conference Call
2022-01-19 11:02 ET
Kidney Doctors, Transplant Providers Work with DaVita in New Government Program to Help Improve the Lives of Medicare Patients with Kidney Disease
2022-01-18 11:02 ET
DaVita Acquires MedSleuth, Deepens Efforts to Improve Transplant Experience
2022-01-12 11:02 ET
DaVita Teammates Transformed Care for Thousands of Patients in 2021
2022-01-06 11:02 ET
DaVita Celebrates 10 Years of Kidney Smart® Educational Programming
2021-12-16 11:02 ET
DaVita Integrated Kidney Care Expands Clinical Leadership Team
2021-12-09 11:02 ET
DaVita's North American Operations Now Powered by 100% Renewable Energy
2021-11-30 11:02 ET
15th Annual Tour DaVita Raises Nearly $1 Million for Bridge of Life
2021-11-29 11:01 ET
DaVita Clinical Research Study Indicates Effectiveness of mRNA COVID-19 Vaccines in Dialysis Patients
2021-11-04 10:04 ET
DaVita Clinical Research to Present New Findings at American Society of Nephrology Kidney Week 2021
2021-11-01 10:01 ET
The American Diabetes Association® and DaVita Raise Awareness about the Link between Diabetes and Kidney Disease during American Diabetes Month®
2021-10-28 20:05 ET
DaVita Inc. 3rd Quarter 2021 Results
2021-10-19 10:01 ET
DaVita Inc. Schedules Virtual Capital Markets Day for November 16, 2021
2021-10-19 10:00 ET
DaVita Inc. Schedules 3rd Quarter 2021 Investor Conference Call
2021-10-11 10:02 ET
DaVita Climate Action Goals Approved by the Science Based Target Initiative
2021-09-16 10:02 ET
DaVita Kidney Care Names New Chief Nursing Officer
2021-09-09 20:02 ET
DaVita Announces Dr. Gregory Moore to Join its Board of Directors
2021-08-03 20:05 ET
DaVita Inc. 2nd Quarter 2021 Results
2021-07-21 08:00 ET
DaVita Inc. Schedules 2nd Quarter 2021 Investor Conference Call
2021-06-10 12:04 ET
DaVita and the National Kidney Foundation Join Forces to Improve Health Equity in Kidney Transplantation
2021-06-02 10:07 ET
Virtual Support Groups Create Community for DaVita Home Dialysis Patients
2021-05-13 10:02 ET
Extraordinary Nurses at DaVita Kidney Care Honored with DAISY Awards
2021-05-10 10:01 ET
DaVita to Further Elevate its Home Dialysis Care Experience with New Baxter Technology
2021-04-29 20:05 ET
DaVita Inc. 1st Quarter 2021 Results
2021-04-27 10:02 ET
DaVita Solidifies Commitment to ESG, Sets 2025 Goals
2021-04-22 20:05 ET
DaVita Inc. Schedules 1st Quarter 2021 Investor Conference Call
2021-04-12 14:00 ET
Blue Cross and Blue Shield of Minnesota Launches Program with DaVita's VillageHealth to Improve Care for Members with Kidney Disease
2021-03-29 10:05 ET
DaVita Shares Strategy for Achieving a Diverse Community Where Everyone Belongs
2021-03-25 15:00 ET
DaVita Statement on Government's Nationwide Program to Vaccinate Dialysis Patients
2021-03-23 12:00 ET
DaVita Kidney Care Expands Use of NxStage Home Hemodialysis Machines from Fresenius Medical Care
2021-03-16 12:00 ET
NephroSant Announces $16 Million Series A, Led by DaVita Venture Group
2021-03-09 08:00 ET
DaVita Inc. to Participate in the 2021 Barclays Global Healthcare Conference
2021-02-24 23:00 ET
DaVita Inc. Announces Upsize and Pricing of Add-On Offering of $1 Billion Senior Notes
2021-02-24 12:44 ET
DaVita Inc. Announces Add-On Offering of $750 Million Senior Notes
2021-02-11 21:06 ET
DaVita Inc. 4th Quarter 2020 Results
2021-01-29 10:48 ET
DaVita Inc. Schedules 4th Quarter 2020 Investor Conference Call
2020-12-22 11:07 ET
DaVita Celebrates 100,000 Patients Receiving Kidney Transplants
2020-11-23 11:04 ET
14th Annual Tour DaVita Raises Nearly $1 Million for Bridge of Life
2020-11-04 07:13 ET
DaVita Responds to Proposition 23 in California
2020-10-29 20:01 ET
DaVita Inc. 3rd Quarter 2020 Results
2020-10-22 13:01 ET
DaVita Clinical Research to Present New Findings at American Society of Nephrology Kidney Week 2020
2020-10-15 20:52 ET
DaVita Inc. Schedules 3rd Quarter 2020 Investor Conference Call
2020-09-17 10:00 ET
DaVita Announces Final Results Of Self-Tender Offer
2020-09-15 10:30 ET
DaVita Announces Preliminary Results of Self-Tender Offer
2020-09-08 10:00 ET
DaVita Announces Shawn Guertin Will Join its Board of Directors
2020-08-27 20:07 ET
DaVita Opens Its Doors to Hurricane Laura Evacuees Needing Dialysis
2020-08-20 10:07 ET
Clinical Research Trials Underway to Study COVID-19 Impact on Dialysis Patients
2020-08-17 08:00 ET
DaVita Commences Self-Tender Offer To Purchase For Cash Shares Of Its Common Stock
2020-08-13 10:17 ET
DaVita Expands Initiative to Advance Nursing Education
2020-08-11 08:30 ET
DaVita Announces Paula A. Price to Join its Board of Directors
2020-08-06 11:27 ET
DaVita Inc. Announces Offering of $1.5 Billion Senior Notes
2020-07-30 20:01 ET
DaVita Inc. 2nd Quarter 2020 Results
2020-07-15 20:01 ET
DaVita Inc. Schedules 2nd Quarter 2020 Investor Conference Call
2020-05-26 12:30 ET
DaVita Inc. Announces Offering of $1.75 Billion Senior Notes
2020-05-05 20:01 ET
DaVita Inc. COVID-19 Response Efforts and 1st Quarter 2020 Results
2020-04-29 10:33 ET
DaVita Reports on 2019 Corporate Social Responsibility Initiatives
2020-04-13 10:00 ET
DaVita Inc. Provides Commentary on the COVID-19 Pandemic
2020-04-13 09:55 ET
DaVita Inc. Schedules 1st Quarter 2020 Investor Conference Call
2020-03-31 21:01 ET
Focus on Patient Care Brings Industry Together to Fight Crisis
2020-03-11 10:14 ET
DaVita Hospital Services Group Names New Chief Medical Officer
2020-02-10 21:01 ET
DaVita Inc. 4th Quarter 2019 Results
2020-01-29 11:00 ET
DaVita Inc. Schedules 4th Quarter 2019 Investor Conference Call
2020-01-22 11:31 ET
DaVita Celebrates 2019 Achievements
2019-11-05 21:01 ET
DaVita Inc. 3rd Quarter 2019 Results
2019-10-29 06:01 ET
DaVita Selects its Next Chief Accounting Officer
2019-10-24 10:42 ET
DaVita Inc. Schedules 3rd Quarter 2019 Investor Conference Call
2019-03-16 00:45 ET
Kay Properties Completes DST 1031 Offering in Baltimore, Maryland
2019-03-01 11:00 ET
Empowering the Kidney Care Community: Kidney Disease Treatment Options to Fit Many Lifestyles
2019-02-21 11:01 ET
DaVita Celebrates 12 Consecutive Years Among FORTUNE® Magazine's World's Most Admired Companies®
2019-02-13 21:29 ET
DaVita Inc. 4th Quarter 2018 Results

SEC forms

Show financial reports only

SEC form 10
2026-05-05 21:03 ET
DaVita published news for 2026 q1
SEC form 8
2026-05-05 20:09 ET
DaVita published news for 2026 q1
SEC form 8
2026-05-05 20:09 ET
DaVita published news for 2026 q1
SEC form 10
2026-02-11 21:06 ET
DaVita published news for 2025 q4
SEC form 8
2026-02-02 16:07 ET
DaVita published news for 2025 q4
SEC form 8
2026-02-02 16:07 ET
DaVita reported for 2025 q4
SEC form 10
2025-10-29 21:05 ET
DaVita published news for 2025 q3
SEC form 8
2025-10-29 20:09 ET
DaVita published news for 2025 q3
SEC form 8
2025-10-29 20:09 ET
DaVita reported for 2025 q3
SEC form 10
2025-08-05 21:03 ET
DaVita published news for 2025 q2
SEC form 8
2025-08-05 20:07 ET
DaVita published news for 2025 q2
SEC form 8
2025-08-05 20:07 ET
DaVita reported for 2025 q2
SEC form 10
2025-05-12 00:00 ET
DaVita reported for 2025 q1
SEC form 8
2025-05-12 00:00 ET
DaVita published news for 2025 q1
SEC form 8
2025-05-12 00:00 ET
DaVita reported for 2025 q1
SEC form 10
2025-02-13 17:25 ET
DaVita reported for 2024 q4
SEC form 8
2025-02-13 16:07 ET
DaVita published news for 2024 q4
SEC form 8
2025-02-13 16:07 ET
DaVita published news for 2024 q4
SEC form 10
2025-02-13 00:00 ET
DaVita published news for 2024 q4
SEC form 10
2024-10-29 17:04 ET
DaVita published news for 2024 q3
SEC form 8
2024-10-29 16:08 ET
DaVita published news for 2024 q3
SEC form 8
2024-10-29 16:08 ET
DaVita reported for 2024 q3
SEC form 10
2024-10-29 00:00 ET
DaVita published news for 2024 q3
SEC form 10
2024-08-06 17:03 ET
DaVita published news for 2024 q2
SEC form 8
2024-08-06 16:10 ET
DaVita published news for 2024 q2
SEC form 8
2024-08-06 16:10 ET
DaVita reported for 2024 q2
SEC form 10
2024-08-06 00:00 ET
DaVita published news for 2024 q2
SEC form 10
2024-05-02 16:12 ET
DaVita reported for 2024 q1
SEC form 8
2024-05-02 16:10 ET
DaVita published news for 2024 q1
SEC form 8
2024-05-02 16:10 ET
DaVita published news for 2024 q1
SEC form 10
2024-05-02 00:00 ET
DaVita published news for 2024 q1
SEC form 10
2024-02-14 00:00 ET
DaVita reported for 2023 q4
SEC form 8
2024-02-13 00:00 ET
DaVita published news for 2023 q4
SEC form 8
2024-02-13 00:00 ET
DaVita published news for 2023 q4
SEC form 10
2023-11-07 17:08 ET
DaVita published news for 2023 q3
SEC form 8
2023-11-07 16:11 ET
DaVita reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
DaVita published news for 2023 q3
SEC form 10
2023-08-03 17:07 ET
DaVita published news for 2023 q2
SEC form 6
2023-08-03 16:08 ET
DaVita reported for 2023 q2
SEC form 10
2023-08-03 00:00 ET
DaVita published news for 2023 q2
SEC form 8
2023-08-03 00:00 ET
DaVita published news for 2023 q2
SEC form 6
2023-07-25 16:42 ET
DaVita published news for 2023 q2
SEC form 6
2023-07-20 18:32 ET
DaVita published news for 2023 q2
SEC form 6
2023-07-13 17:16 ET
DaVita published news for 2023 q2
SEC form 6
2023-06-15 16:28 ET
DaVita published news for 2023 q1
SEC form 6
2023-06-08 16:47 ET
DaVita published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
DaVita published news for 2023 q1
SEC form 8
2023-05-08 00:00 ET
DaVita published news for 2023 q1
SEC form 6
2023-03-21 06:22 ET
DaVita published news for 2022 q4
SEC form 10
2023-02-22 17:19 ET
DaVita published news for 2022 q4
SEC form 6
2023-02-22 16:09 ET
DaVita published news for 2022 q4
SEC form 10
2023-02-22 00:00 ET
DaVita reported for 2022 q4
SEC form 8
2023-02-22 00:00 ET
DaVita reported for 2022 q4
SEC form 10
2022-10-31 00:00 ET
DaVita reported for 2022 q3
SEC form 10
2022-10-28 18:02 ET
DaVita published news for 2022 q3
SEC form 6
2022-10-28 06:33 ET
DaVita published news for 2022 q3
SEC form 8
2022-10-28 00:00 ET
DaVita reported for 2022 q3
SEC form 6
2022-10-18 16:48 ET
DaVita published news for 2022 q3
SEC form 6
2022-09-29 18:38 ET
DaVita published news for 2022 q2
SEC form 6
2022-09-13 17:17 ET
DaVita published news for 2022 q2
SEC form 10
2022-08-01 17:07 ET
DaVita published news for 2022 q2
SEC form 6
2022-08-01 16:10 ET
DaVita published news for 2022 q2
SEC form 10
2022-08-01 00:00 ET
DaVita reported for 2022 q2
SEC form 8
2022-08-01 00:00 ET
DaVita reported for 2022 q2
SEC form 6
2022-06-21 16:38 ET
DaVita published news for 2022 q1
SEC form 6
2022-06-14 16:29 ET
DaVita published news for 2022 q1
SEC form 6
2022-05-26 06:45 ET
DaVita published news for 2022 q1
SEC form 6
2022-05-16 06:19 ET
DaVita published news for 2022 q1
SEC form 10
2022-05-05 17:07 ET
DaVita published news for 2022 q1
SEC form 6
2022-05-05 16:08 ET
DaVita published news for 2022 q1
SEC form 10
2022-05-05 00:00 ET
DaVita reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
DaVita reported for 2022 q1
SEC form 6
2022-04-25 06:16 ET
DaVita published news for 2022 q1
SEC form 6
2022-04-07 18:34 ET
DaVita published news for 2022 q1
SEC form 10
2022-02-11 16:07 ET
DaVita published news for 2021 q4
SEC form 10
2022-02-11 00:00 ET
DaVita published news for 2021 q4
SEC form 6
2022-02-10 16:08 ET
DaVita published news for 2021 q4
SEC form 8
2022-02-10 00:00 ET
DaVita published news for 2021 q4
SEC form 6
2022-02-09 17:03 ET
DaVita published news for 2021 q4
SEC form 6
2021-12-17 17:16 ET
DaVita published news for 2021 q3
SEC form 10
2021-10-28 17:04 ET
DaVita published news for 2021 q3
SEC form 6
2021-10-28 16:09 ET
DaVita published news for 2021 q3
SEC form 10
2021-10-28 00:00 ET
DaVita published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
DaVita published news for 2021 q3
SEC form 6
2021-09-16 16:56 ET
DaVita published news for 2021 q2
SEC form 6
2021-09-09 16:48 ET
DaVita published news for 2021 q2
SEC form 10
2021-08-03 17:04 ET
DaVita published news for 2021 q2
SEC form 6
2021-08-03 16:09 ET
DaVita published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
DaVita published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
DaVita published news for 2021 q2
SEC form 6
2021-06-23 20:08 ET
DaVita published news for 2021 q1
SEC form 6
2021-06-14 16:58 ET
DaVita published news for 2021 q1
SEC form 6
2021-05-21 16:38 ET
DaVita published news for 2021 q1
SEC form 10
2021-04-29 17:06 ET
DaVita published news for 2021 q1
SEC form 6
2021-04-29 16:09 ET
DaVita published news for 2021 q1
SEC form 10
2021-04-29 00:00 ET
DaVita published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
DaVita published news for 2021 q1
SEC form 6
2021-04-23 16:49 ET
DaVita published news for 2021 q1
SEC form 6
2021-03-09 06:04 ET
DaVita published news for 2020 q4
SEC form 6
2021-02-26 16:25 ET
DaVita published news for 2020 q4
SEC form 6
2021-02-24 18:11 ET
DaVita published news for 2020 q4
SEC form 6
2021-02-24 08:17 ET
DaVita published news for 2020 q4
SEC form 10
2021-02-12 16:07 ET
DaVita published news for 2020 q4
SEC form 6
2021-02-11 16:10 ET
DaVita published news for 2020 q4
SEC form 6
2020-12-10 16:48 ET
DaVita published news for 2020 q3
SEC form 6
2020-11-13 16:16 ET
DaVita published news for 2020 q3
SEC form 10
2020-10-29 17:05 ET
DaVita published news for 2020 q3
SEC form 6
2020-10-29 16:14 ET
DaVita published news for 2020 q3
SEC form 6
2020-10-05 06:25 ET
DaVita published news for 2020 q3